DECODING MYOTONIC DYSTROPHY TYPE 1: INTEGRATIVE INSIGHTS INTO DISEASE ORIGINS, MOLECULAR PATHOGENESIS, DIAGNOSIS AND EMERGING THERAPEUTIC STRATEGIES

Abstract

Background: Myotonic Dystrophy Type 1 (DM1) (OMIM 160900) is a dominant autosomal, multisystem illness noticeable by many phenotypic expressions and a progressively worsening disease course. It is the most predominant muscular dystrophy between adults and is categorized by its miscellaneous symptoms and significant effect on value of life.

Objective: This review pursues to deliver a widespread summary of DM1, about its history, prevalence, causes, indications, pathogenesis, genetic underpinning, and present diagnostic and treatment methods.

Methods: A thorough literature review was performed, focused on historical progress, molecular mechanisms, medical symptoms, and therapeutic approaches linked with DM1. Data were gathered from several scholarly sources and original study papers.

Results: DM1 was firstly recognized in 1909 and has been linked with CTG repeat extensions in the DMPK gene since then. Epidemiologic research shows differing incidences of DM1 in various regions, with greater incidences in Europe than in Asia. The disorder is characterized by a variation of symptoms such as breathing difficulties, muscle weakness, hormonal imbalances, heart irregularities, and neurological difficulties. The central pathogenesis includes harmful RNA gain-of-function effects caused by prolonged CTG repeats. Although a cure is not available, supportive therapies and new gene treatments provide promise for alleviating symptoms and possibly fixing the root genetic issues.

Conclusions: DM1 continues to be a difficult condition due to its intricate pathophysiology. Progress in molecular genetics and treatment approaches, such as gene editing techniques, is setting the stage for enhanced management and possible future therapies.